BlueOcean Ventures II became the very first tokenized medtech VC fund with the launch of a dedicated ICO platform SwissVCToken to allow token holders to gain profit from startup investments.
BlueOcean Ventures II is the first tokenized medtech VC fund.
It just announced the launch of SwissVCToken, a platform that’s dedicated to the sale of the BlueOcean Ventures II BOV Token.
BlueOcean Ventures II supports the developments of medtech
BlueOcean Ventures II supports medical device and life science startups which aim to enable the development of innovations that make the world a healthier place to be in.
Medtech creates virtual ways of diagnosing, monitoring and treating various health issues in the world.
It streamlines healthcare services, offers urgent aid, and builds innovative devices that resolve patients’ needs. In other words, medtech sustains health in a really productive way.
There are lots of products that have been created by medtech startups to provide treatment and prevent disease.
The medtech industry continues to grow and develop equipment to save lives.
BlueOcean Ventures II is focused on investing in medical devices and diagnostics companies that are located in Europe and startups in the life sciences, nanotech and digital health sectors as well.
The company uses a large network of expert advisors and industry contacts to build, manage and coach the startups it invests in.
Selling the BOV Token
BlueOcean Ventures II invested in five startups Ava (best Swiss startup in 2017 and 2018), Rheon Medical, Volumina Medical, Luciole Medical and Abionic.
Via the STO platform, BlueOcean will sell the BOV Token which is backed by real assets and based on the value of the existing portfolio companies.
The token allows investors to gain profit from the company’s portfolio companies.
This is the first tokenized fund that offers crypto investors access to a medtech fund that BlueOcean holds.
Investors will be able to enjoy high liquidity and accessibility regarding both crypto and fiat payment options.
BlueOcean transforms the highly illiquid Venture Capital asset class into a tradable asset.
The presale of 5million tokens will begin on October 15th. It will continue with 20 million tokens at a 30% bonus until November 30th. All the STO net proceeds will be invested in BlueOcean Ventures II.
Emmanuel de Watteville, General Partner and Co-Founder of BlueOcean Ventures ll says that the company’s mission is to enable innovative medtech startups to develop new devices and treatments.
They are also providing a means to shareholding and profit gain without the volatility of traditional cryptos.